Type III hyperlipoproteinemia (Type III), which is characterized by an abnormal accumulation of intermediate density lipoprotein (ILDL, remnant), cannot be diagnosed by the measurements of the serum cholesterol and triglyceride only. Proving “β-VLDL” by ultracentrifugation and lipoprotein electrophoresis has been a specific diagnostic test for Type III. However, electrophoretic determination of the presence of β-migrating VLDL requires subjective interpretation and yields only qualitative information. In fact, “β-VLDL” has recently been proved not to be specific for Type III. Thus, various chemical criteria have been proposed to be more specific and sensitive for Type III by many authors, but none of these criteria are satisfactory at present.
In an effort to find a more specific and sensitive chemical criteria, we made serial determinations of serum lipids and lipoproteins in three patients who are thought to be typical Type III by the clinical features and the presence of broad-β and β-VLDL, and compared the results with those of other types of hyperlipoproteinemia.
The results were as follows:
1) The serum cholesterol and triglyceride levels of Type III ranged from 182 to 540mg/dl and from 142 to 898mg/dl respectively. Type III could not be differentiated from Type IIb and IV by the serum levels of cholesterol and triglyceride only. The cholesterol/triglyceride ratio in Type III was within 0.53-1.75 range and showed overlap with the ratios in normal subjects, Type IIb and IV.
2) The VLDL-cholesterol levels in all samples of Type III were greater than 50mg/dl, but in one of nine Type IIb and one of five Type IV the VLDL-cholesterol levels were greater than 50mg/dl.
3) The VLDL-cholesterol/VLDL-Triglyceride ratios in Type III were between 0.27 and 1.93, and were found to be useful in differentiating Type III from normal subjects, Type IIa and IIb. However, it was impossible to differentiate Type III from Type IV by the ratio.
4) The VLDL-cholesterol/cholesterol ratios in Type III were above 0.15 in contrast to normal subjects, Type IIa and IIb, but the ratio was of little use in differentiating Type III from Type IV.
5) The VLDL-cholesterol/triglyceride ratios in Type III were greater than 0.20, but a few patients with normal serum lipids, Type IIa and IIb showed ratios greater than 0.20. Ratio above 0.30, which is the criterion for Type III introduced by Fredrickson et al., was proved to be definite for Type III. However, in 13 out of 28 samples of Type III the ratios were less than 0.30.
6) From the present study, it seemed to be logical to conclude that the VLDL-cholesterol/VLDL-triglyceride ratio above 0.33 should be considered as diagnostic of Type III, when the VLDL-cholesterol is above 55mg/dl.
View full abstract